Ron Rosen, MD
Nuclear Medicine · San Jose, CANPI 1750331468
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by Telix Pharmaceuticals at 47.7% of the total. 2025 is the largest year on record at $181, more than ten times the $18 reported in 2019.
Across 8 payments — averaging $34.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Telix Pharmaceuticals$133
- Novartis$31
- Lilly USA, LLC$28
- Gilead$24
- Progenics Pharmaceuticals, Inc.$23
- Blue Earth Diagnostics$22
- plus $18 from 1 others
What the payments were for
- Food & beverage$279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Telix Pharmaceuticals | 2 | $133 |
| Novartis | 1 | $31 |
| Lilly USA, LLC | 1 | $28 |
| Gilead | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $23 |
| Blue Earth Diagnostics | 1 | $22 |
| AstraZeneca | 1 | $18 |
How this compares
$279 in reported general payments places this provider in the 75th percentile of 110 nuclear medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nuclear medicine in San Jose
- Hossein JadvarLos Angeles$294K
- Michael DaeSan Francisco$45K
- Ernest BelezzuoliSan Diego$39K
- Johannes CzerninLos Angeles$24K
- Gholam BerenjiLos Angeles$15K
- Frankis AlmaguelSan Bernardino$13K
- Shahram BonyadlouLos Angeles$12K
- Leonard ValentinoRedwood City$8K
- Randy YehSylmar$8K
- Daniel SilvermanLos Angeles$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.